Xtl Biopharmaceuticals (XTLB) Net Equity Issued and Repurchased (2011 - 2015)

Xtl Biopharmaceuticals (XTLB) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $3.6 million the latest figure, recorded in Q2 2015.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $3.6 million in Q2 2015, while the trailing twelve-month figure through Dec 2015 was $3.6 million (changed N/A YoY) and the FY2024 annual result came in at $1.5 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased rose to $3.6 million in Q2 2015 per XTLB's latest filing, from -$19000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for XTLB reached as high as $3.6 million in Q2 2015 and fell as low as -$19000.0 in Q2 2012.
• A 3-year average of $1.3 million and a median of $878000.0 in 2011 frame the typical range for Net Equity Issued and Repurchased.
• The largest YoY upside for Net Equity Issued and Repurchased was 38.0% in 2012 against a maximum downside of 26.67% in 2012.
• Year by year, Net Equity Issued and Repurchased stood at -$10000.0 in 2011, then slumped by 90.0% to -$19000.0 in 2012, then surged by 18831.58% to $3.6 million in 2015.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $3.6 million, -$19000.0, and $2.4 million for Q2 2015, Q2 2012, and Q1 2012 respectively.